Despite excellent clinical results for sirolimus (rapamycin)-eluting stents, the exact mechanisms of antirestenotic activity and affected cellular targets are incompletely understood. Therefore, we determined the presence and tem- porospatial expression pattern of FKBP12, the primary intracellular receptor of rapamycin, in rat carotid arteries after balloon injury, as well as in human in-stent restenosis and primary stable coronary atheroma. FKBP12 expression was assessed by immunohistochemistry. Rat carotid arteries revealed maximal expression in 57.7 ± 4.0% of neointimal cells at day 7. A large proportion of these FKBP12+ cells showed luminally confined co-expression with dendritic cell markers. Despite a considerably thicker neointima at day 28, presence of FKBP12 decreased (8.5 ± 1.9%, p = 0.02) with a scattered pattern in luminal and deep neointima. Likewise, human in-stent restenosis atherectomy specimens (time after stent implantation 2–12 months) revealed a comparable extent of cellular rapamycin receptor expression (9.3 ± 1.0%) that significantly differed from that found in primary stable atheroma (1.3 ± 0.4%, p < 0.001). In conclusion, the rapamycin receptor is predominantly present during early neointima formation, while mature neointimal atheromas show a relatively low expression without confinement to luminal areas. Co-expression of FKBP12 and dendritic cell markers suggests that dendritic cells may be another important target for early and long-term rapamycin effects.

1.
Sousa JE, Costa MA, Abizaid A, Rensing BJ, Abizaid AS, Tanajury LF, Kozuma K, Van Langenhove G, Sousa AG, Falotica R, Jaeger J, Popma JJ, Serruys PW: Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries – a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation2001;103:192–195.
2.
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R; RAVEL Study Group: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med2002;346:1773–1780.
3.
Holmes DR, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE: Analysis of 1-year clinical outcomes in the SIRIUS Trial – a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634–640.
4.
Sousa JE, Serruys PW, Costa MA: Drug-eluting stents. Part I. Circulation 2003;107:2274–2279.
5.
Degertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Vos J, Smits PC, van der Giessen WJ, van den Brand M, de Feyter P, Popma JJ: Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation – long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002;106:1610–1613.
6.
Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, Feres F, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW: Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107:381–383.
7.
Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, McFadden E, Sianos G, Hofma SH, Smits PC, van der Giessen WJ, de Feyter PJ: Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the ‘real world’: The Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190–195.
8.
Finkelstein A, McClean D, Kar S, Takizawa K, Varghese K, Baek N, Park K, Fishbein MC, Makkar R, Litvack F, Eigler NL: Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 2003;107:777–784.
9.
Bennett MR: In-stent restenosis: pathology and implications for the development of drug eluting stents. Heart 2003;89:218–224.
10.
Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, Badimon JJ: Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99:2164–2170.
11.
Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R: Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002;105:2974–2980.
12.
Danenberg HD, Golomb G, Groothuis A, Gao J, Epstein H, Swaminathan RV, Seifert P, Edelman ER: Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation 2003;108:2798–2804.
13.
Fukuda D, Shimada K, Tanaka A, Kawarabayashi T, Yoshiyama M, Yoshikawa J: Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol 2004;43:18–23.
14.
Bauriedel G, Jabs A, Skowasch D, Hutter R, Badimon JJ, Fuster V, Welsch U, Lüderitz B: Dendritic cells in neointima formation after rat carotid balloon injury – coordinated expression with anti-apoptotic Bcl-2 and HSP47 in arterial repair. J Am Coll Cardiol 2003;42:930–938.
15.
Skowasch D, Jabs A, Andrié R, Dinkelbach S, Lüderitz B, Bauriedel G: Presence of bone-marrow and neural-crest derived cells in intimal hyperplasia at the time of clinical in-stent restenosis. Cardiovasc Res 2003;60:684–691.
16.
Sehgal SN: Rapamune (RAPA, rapamycin, sirolimus) – mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335–340.
17.
Abdelmeguid AE, Ellis GS, Sapp SK, Simpfendorfer C, Franco I, Whitlow PL: Directional atherectomy in unstable angina. J Am Coll Cardiol 1994;24:46–54.
18.
Simonton CA, Leon MB, Baim DS, Hinohara T, Kent KM, Bersin RM, Wilson BH, Mintz GS, Fitzgerald PJ, Yock PG, Popma JJ, Ho KK, Cutlip DE, Senerchia C, Kuntz RE: Optimal directional coronary atherectomy. Final results of the optimal atherectomy restenosis study (OARS). Circulation 1998;97:332–339.
19.
Skowasch D, Jabs A, Andrié R, Dinkelbach S, Schiele TM, Wernert N, Lüderitz B, Bauriedel G: Pathogen burden, inflammation, proliferation and apoptosis in human in-stent restenosis. Tissue characteristics compared to primary atherosclerosis. J Vasc Res 2004;41:525–534.
20.
Zohlnhöfer D, Klein CA, Richter T, Brandl R, Murr A, Nuhrenberg T, Schomig A, Baeurele PA, Neumann FJ: Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy – detection of FK506-binding protein 12 upregulation. Circulation 2001;103:1396–1402.
21.
Woltman AM, de Fijter JW, Kamerling SW, van Der Kooji SW, Paul LC, Daha MR, van Kooten C: Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001;98:174–180.
22.
Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM: Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005;46:231–236.
23.
Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PS, McFadden EP, Sianos G, Lighart JM, van Essen D, de Feyter PJ, Serruys PW: Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006;27:166–170.
24.
Meier P, Zbinden R, Togni M, Wenaweser P, Windecker S, Meier B, Seiler C: Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol 2007;49:15–21.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.